

Freedom of Information Act 2000 - Request Reference FoI/22/596

Haemophilia A

Q1. How many patients are registered with your Haemophilia Centre for:

- Haemophilia A - 328
- Haemophilia A – severe disease - 79
- Haemophilia A – moderate disease – 21
- Haemophilia A – mild disease - 228

Q2. In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate - 10
- Adynovi - *
- Elocta - 6
- Esperoct - *
- Factor Eight Inhibitor Bypass Activity (FEIBA) - 0
- Hemlibra (standalone) - *
- Hemlibra in combination with any Factor VIII - *
- NovoEight - 0
- NovoSeven RT - 0
- Obizur - 0
- Refacto AF - 0

Q3. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate -6
- Adynovi - *
- Elocta - 6
- Esperoct - *
- Factor Eight Inhibitor Bypass Activity (FEIBA) - 0
- Hemlibra (standalone) - *
- Hemlibra in combination with any Factor VIII - *
- NovoEight - 0
- NovoSeven RT - 0
- Obizur - 0
- Refacto AF – 0

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information in the above table has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.